These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 22024360)

  • 1. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
    Uversky VN; Eliezer D
    Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
    Tavassoly O; Lee JS
    FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
    Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.
    Beyer K
    Cell Biochem Biophys; 2007; 47(2):285-99. PubMed ID: 17652776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The aggregation and fibrillation of alpha-synuclein.
    Fink AL
    Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
    Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
    Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.
    Berrocal R; Vasquez V; Rao Krs S; Gadad BS; Rao KS
    Mol Neurobiol; 2015; 51(3):1417-31. PubMed ID: 25139280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
    Busquets MA; Espargaró A; Estelrich J; Sabate R
    Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
    Lee YC; Hsu SD
    Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
    Engelender S
    Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.